Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates (ADCs) ...

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

WEREWOLF ®, the WEREWOLF logo, PREDATOR ®, INDUKINE ™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today ...

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...

City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States and a ...

Nektar Therapeutics is waiting on multiple data ... and is focusing on five indications across melanoma, bladder cancer, and kidney cancer for the Opdivo (nivolumab) and bempeg combination.

Dr. Baynes, a seasoned expert in hematology and oncology ... candidates in the United States. This press release statement is based on information provided by Nurix Therapeutics, Inc. It contains ...